124 related articles for article (PubMed ID: 23569129)
1. Clinical significance of protocadherin-8 (PCDH8) promoter methylation in bladder cancer.
Lin YL; Ma JH; Luo XL; Guan TY; Li ZG
J Int Med Res; 2013 Feb; 41(1):48-54. PubMed ID: 23569129
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.
Lin YL; Wang YL; Ma JG; Li WP
J Exp Clin Cancer Res; 2014 Aug; 33(1):68. PubMed ID: 25927589
[TBL] [Abstract][Full Text] [Related]
3. Protocadherin-17 promoter methylation in serum-derived DNA is associated with poor prognosis of bladder cancer.
Luo ZG; Li ZG; Gui SL; Chi BJ; Ma JG
J Int Med Res; 2014 Feb; 42(1):35-41. PubMed ID: 24366498
[TBL] [Abstract][Full Text] [Related]
4. Protocadherin 17 promoter methylation in tumour tissue from patients with bladder transitional cell carcinoma.
Wang XB; Lin YL; Li ZG; Ma JH; Li J; Ma JG
J Int Med Res; 2014 Apr; 42(2):292-9. PubMed ID: 24567353
[TBL] [Abstract][Full Text] [Related]
5. Clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in bladder cancer.
Lin YL; Li ZG; He ZK; Guan TY; Ma JG
J Int Med Res; 2012; 40(6):2117-23. PubMed ID: 23321168
[TBL] [Abstract][Full Text] [Related]
6. Aberrant Promoter Methylation of Protocadherin8 (PCDH8) in Serum is a Potential Prognostic Marker for Low Gleason Score Prostate Cancer.
Lin YL; Li YL; Ma JG
Med Sci Monit; 2017 Oct; 23():4895-4900. PubMed ID: 29026066
[TBL] [Abstract][Full Text] [Related]
7. Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma.
Lin YL; Liu XQ; Li WP; Sun G; Zhang CT
Int Urol Nephrol; 2012 Feb; 44(1):111-7. PubMed ID: 21516472
[TBL] [Abstract][Full Text] [Related]
8. Aberrant methylation of CDH13 is a potential biomarker for predicting the recurrence and progression of non muscle invasive bladder cancer.
Lin YL; Xie PG; Ma JG
Med Sci Monit; 2014 Sep; 20():1572-7. PubMed ID: 25196672
[TBL] [Abstract][Full Text] [Related]
9. The clinical significance of PCDH10 promoter methylation in patients with bladder transitional cell carcinoma.
Lin YL; Li ZG; Guan TY
Urol Int; 2013; 90(2):219-24. PubMed ID: 23171734
[TBL] [Abstract][Full Text] [Related]
10. Expression of protocadherin8: Function as a tumor suppressor in hypopharyngeal carcinoma.
Li Y; Liu C; Wang Z; Hu G
Cancer Biomark; 2018; 22(3):495-502. PubMed ID: 29865037
[TBL] [Abstract][Full Text] [Related]
11. Frequent silencing of protocadherin 8 by promoter methylation, a candidate tumor suppressor for human gastric cancer.
Zhang D; Zhao W; Liao X; Bi T; Li H; Che X
Oncol Rep; 2012 Nov; 28(5):1785-91. PubMed ID: 22941331
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma.
Lin YL; Sun G; Liu XQ; Li WP; Ma JG
J Int Med Res; 2011; 39(1):179-86. PubMed ID: 21672320
[TBL] [Abstract][Full Text] [Related]
13. Association between protocadherin 8 promoter hypermethylation and the pathological status of prostate cancer.
Zhang P; Wang H; Wang J; Liu Q; Wang Y; Feng F; Shi L
Oncol Lett; 2017 Aug; 14(2):1657-1664. PubMed ID: 28789392
[TBL] [Abstract][Full Text] [Related]
14. Hypermethylation of E-cadherin, p16, p14, and RASSF1A genes in pathologically normal urothelium predict bladder recurrence of bladder cancer after transurethral resection.
Lin HH; Ke HL; Wu WJ; Lee YH; Chang LL
Urol Oncol; 2012; 30(2):177-81. PubMed ID: 20800513
[TBL] [Abstract][Full Text] [Related]
15. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
[TBL] [Abstract][Full Text] [Related]
16. Aberrant methylation of PCDH8 is a potential prognostic biomarker for patients with clear cell renal cell carcinoma.
Lin YL; Wang YL; Fu XL; Ma JG
Med Sci Monit; 2014 Nov; 20():2380-5. PubMed ID: 25416427
[TBL] [Abstract][Full Text] [Related]
17. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
18. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer.
Harada H; Miyamoto K; Yamashita Y; Taniyama K; Mihara K; Nishimura M; Okada M
Cancer Med; 2015 Oct; 4(10):1536-46. PubMed ID: 26276761
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of protocadherin-10 expression correlates with malignant behaviour and poor prognosis in human bladder cancer.
Ma JG; He ZK; Ma JH; Li WP; Sun G
J Int Med Res; 2013 Feb; 41(1):38-47. PubMed ID: 23569128
[TBL] [Abstract][Full Text] [Related]
20. Gene Expression, DNA Methylation and Prognostic Significance of DNA Repair Genes in Human Bladder Cancer.
Wojtczyk-Miaskowska A; Presler M; Michajlowski J; Matuszewski M; Schlichtholz B
Cell Physiol Biochem; 2017; 42(6):2404-2417. PubMed ID: 28848075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
